ACADIA PHARMACEUTICALS INC. Accrued Royalties, Current
ACADIA PHARMACEUTICALS INC. (ACAD) had Accrued Royalties, Current of $2.45 million as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes
us-gaap:AccruedRoyaltiesCurrent · last filed 2021-02-25
- 2020-12-31: Accrued Royalties, Current $2.45M.
- 2020-09-30: Accrued Royalties, Current $2.44M.
- 2020-06-30: Accrued Royalties, Current $2.21M.
- 2020-03-31: Accrued Royalties, Current $3.78M.
| Period end | Accrued Royalties, Current |
|---|---|
| 2020-12-31 | $2.45M 10-K · filed 2021-02-25 |
| 2020-09-30 | $2.44M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $2.21M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.78M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.97M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.92M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $1.68M 10-Q · filed 2019-08-01 |
| 2018-12-31 | $1.20M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |